Cargando…

The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up

SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrés, Abel, Reyes, Luís, Di Somma, Alberto, Topczewski, Thomaz, Mosteiro, Alejandra, Guizzardi, Giulia, De Rosa, Andrea, Halperin, Irene, Hanzu, Felicia, Mora, Mireia, Alobid, Isam, Aldecoa, Iban, Bargalló, Núria, Enseñat, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818833/
https://www.ncbi.nlm.nih.gov/pubmed/36612263
http://dx.doi.org/10.3390/cancers15010267
_version_ 1784865082905198592
author Ferrés, Abel
Reyes, Luís
Di Somma, Alberto
Topczewski, Thomaz
Mosteiro, Alejandra
Guizzardi, Giulia
De Rosa, Andrea
Halperin, Irene
Hanzu, Felicia
Mora, Mireia
Alobid, Isam
Aldecoa, Iban
Bargalló, Núria
Enseñat, Joaquim
author_facet Ferrés, Abel
Reyes, Luís
Di Somma, Alberto
Topczewski, Thomaz
Mosteiro, Alejandra
Guizzardi, Giulia
De Rosa, Andrea
Halperin, Irene
Hanzu, Felicia
Mora, Mireia
Alobid, Isam
Aldecoa, Iban
Bargalló, Núria
Enseñat, Joaquim
author_sort Ferrés, Abel
collection PubMed
description SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity, and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. ABSTRACT: Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26–156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy’s and Knosp’s grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp’s grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET.
format Online
Article
Text
id pubmed-9818833
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98188332023-01-07 The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up Ferrés, Abel Reyes, Luís Di Somma, Alberto Topczewski, Thomaz Mosteiro, Alejandra Guizzardi, Giulia De Rosa, Andrea Halperin, Irene Hanzu, Felicia Mora, Mireia Alobid, Isam Aldecoa, Iban Bargalló, Núria Enseñat, Joaquim Cancers (Basel) Article SIMPLE SUMMARY: Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity, and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. ABSTRACT: Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26–156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy’s and Knosp’s grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp’s grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp’s grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET. MDPI 2022-12-30 /pmc/articles/PMC9818833/ /pubmed/36612263 http://dx.doi.org/10.3390/cancers15010267 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferrés, Abel
Reyes, Luís
Di Somma, Alberto
Topczewski, Thomaz
Mosteiro, Alejandra
Guizzardi, Giulia
De Rosa, Andrea
Halperin, Irene
Hanzu, Felicia
Mora, Mireia
Alobid, Isam
Aldecoa, Iban
Bargalló, Núria
Enseñat, Joaquim
The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title_full The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title_fullStr The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title_full_unstemmed The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title_short The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
title_sort prognostic-based approach in growth hormone-secreting pituitary neuroendocrine tumors (pitnet): tertiary reference center, single senior surgeon, and long-term follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818833/
https://www.ncbi.nlm.nih.gov/pubmed/36612263
http://dx.doi.org/10.3390/cancers15010267
work_keys_str_mv AT ferresabel theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT reyesluis theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT disommaalberto theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT topczewskithomaz theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT mosteiroalejandra theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT guizzardigiulia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT derosaandrea theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT halperinirene theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT hanzufelicia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT moramireia theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT alobidisam theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT aldecoaiban theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT bargallonuria theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT ensenatjoaquim theprognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT ferresabel prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT reyesluis prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT disommaalberto prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT topczewskithomaz prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT mosteiroalejandra prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT guizzardigiulia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT derosaandrea prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT halperinirene prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT hanzufelicia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT moramireia prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT alobidisam prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT aldecoaiban prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT bargallonuria prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup
AT ensenatjoaquim prognosticbasedapproachingrowthhormonesecretingpituitaryneuroendocrinetumorspitnettertiaryreferencecentersingleseniorsurgeonandlongtermfollowup